MiRNA and lung cancer radiosensitivity: a mini-review

Area of Science:

• Oncology
• Molecular Biology
• Radiotherapy Research

Background:

• Radiotherapy (RTH) is a primary treatment for locally advanced or advanced lung cancer.
• Predicting RTH outcomes based solely on clinical features is challenging.
• Established molecular markers for RTH efficacy prediction are lacking.

Purpose of the Study:

• To review the role of microRNAs (miRNAs) as potential biomarkers in predicting lung cancer response to radiotherapy.
• To explore the utility of miRNAs in patient selection and toxicity risk assessment for RTH.

Main Methods:

• Review of recent experimental studies (cell culture analysis).
• Analysis of clinical studies investigating miRNAs and lung tumor sensitivity to RTH.

Main Results:

• miRNAs are emerging as promising biomarkers for RTH response prediction in lung cancer.
• miRNAs may aid in selecting patients who will benefit from RTH.
• miRNAs can potentially estimate the risk of post-irradiation toxicity.

Conclusions:

• miRNAs offer a promising avenue for improving personalized lung cancer treatment through radiotherapy.
• The accessibility of miRNA testing in blood samples makes them attractive predictive markers.
• Further research into miRNAs could enhance the efficacy and safety of lung cancer radiotherapy.